NCT04970251

Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma

Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Siriraj Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Purpose: To investigate intravitreal aflibercept (IVA) injection as an adjunctive treatment to trabeculectomy with mitomycin C (TMC) and panretinal photocoagulation (PRP) for neovascular glaucoma (NVG). Setting: Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand Study design: Prospective interventional case series Methods: PRP and IVA (2 mg/0.05 ml) injection were given, and TMC was performed within 2 weeks after IVA. Additional PRP, laser suture lysis, subconjunctival 5-fluorouracil injection, and bleb needling were performed after TMC if indicated. Best-collected visual acuity (BCVA), intraocular pressure (IOP), surgical complications, and number of anti-glaucoma medications were collected.

Conditions

• Intraocular Pressure
• Neovascular Glaucoma
• Vascular Endothelial Growth Factor Overexpression
• Glaucoma Secondary to Eye Inflammation

Interventions

Type	Name	Description
DRUG	Aflibercept Ophthalmic	Panretinal photocoagulation and intravitreal aflibercept (2 mg/0.05 ml) injection were given, and trabeculectomy with mitomycin C was performed within 2 weeks after intravitreal aflibercept injection.

Timeline

• Start date: 2018-11-01
• Primary completion: 2021-03-31
• Completion: 2021-03-31
• First posted: 2021-07-21
• Last updated: 2021-07-21

Locations

1 site across 1 country: Thailand